O	0	10	Regulation	Regulation	NN	B-NP
O	11	13	of	of	IN	B-PP
O	14	28	thrombospondin	thrombospondin	NN	B-NP
O	28	29	-	-	HYPH	B-NP
O	29	30	1	1	CD	I-NP
O	31	33	by	by	IN	B-PP
O	34	41	natural	natural	JJ	B-NP
O	42	45	and	and	CC	I-NP
O	46	55	synthetic	synthetic	JJ	I-NP
O	56	66	progestins	progestin	NNS	I-NP
O	67	69	in	in	IN	B-PP
O	70	75	human	human	JJ	B-NP
B-Cell	76	82	breast	breast	NN	I-NP
I-Cell	83	89	cancer	cancer	NN	I-NP
I-Cell	90	95	cells	cell	NNS	I-NP
O	95	96	.	.	.	O

O	97	100	Our	Our	PRP$	B-NP
O	101	107	recent	recent	JJ	I-NP
O	108	115	studies	study	NNS	I-NP
O	116	120	show	show	VBP	B-VP
O	121	125	that	that	IN	B-SBAR
O	126	136	progestins	progestin	NNS	B-NP
O	137	143	induce	induce	VBP	B-VP
O	144	152	vascular	vascular	JJ	B-NP
O	153	164	endothelial	endothelial	JJ	I-NP
O	165	171	growth	growth	NN	I-NP
O	172	178	factor	factor	NN	I-NP
O	179	180	(	(	(	O
O	180	184	VEGF	VEGF	NN	B-NP
O	184	185	)	)	)	O
O	186	188	in	in	IN	B-PP
B-Cell	189	195	breast	breast	NN	B-NP
I-Cell	196	202	cancer	cancer	NN	I-NP
I-Cell	203	208	cells	cell	NNS	I-NP
O	209	213	that	that	WDT	B-NP
O	214	221	express	express	VBP	B-VP
O	222	228	mutant	mutant	JJ	B-NP
O	229	232	p53	p53	NN	I-NP
O	233	240	protein	protein	NN	I-NP
O	240	241	.	.	.	O

O	242	246	Here	Here	RB	B-ADVP
O	246	247	,	,	,	O
O	248	250	we	we	PRP	B-NP
O	251	255	show	show	VBP	B-VP
O	256	260	that	that	IN	B-SBAR
O	261	268	natural	natural	JJ	B-NP
O	269	272	and	and	CC	I-NP
O	273	282	synthetic	synthetic	JJ	I-NP
O	283	293	progestins	progestin	NNS	I-NP
O	294	298	also	also	RB	B-ADVP
O	299	305	induce	induce	VBP	B-VP
O	306	320	thrombospondin	thrombospondin	NN	B-NP
O	320	321	-	-	HYPH	B-NP
O	321	322	1	1	CD	I-NP
O	323	324	(	(	(	O
O	324	327	TSP	TSP	NN	O
O	327	328	-	-	HYPH	O
O	328	329	1	1	CD	O
O	329	330	)	)	)	O
O	331	335	mRNA	mRNA	NN	B-NP
O	336	339	and	and	CC	I-NP
O	340	347	protein	protein	NN	I-NP
O	348	350	in	in	IN	B-PP
B-Cell	351	354	T47	T47	NN	B-NP
I-Cell	354	355	-	-	HYPH	B-NP
I-Cell	355	356	D	D	NN	I-NP
O	357	360	and	and	CC	I-NP
B-Cell	361	363	BT	BT	NN	I-NP
I-Cell	363	364	-	-	HYPH	I-NP
I-Cell	364	367	474	474	CD	I-NP
I-Cell	368	374	breast	breast	NN	I-NP
I-Cell	375	381	cancer	cancer	NN	I-NP
I-Cell	382	387	cells	cell	NNS	I-NP
O	387	388	.	.	.	O

O	389	402	Antiprogestin	Antiprogestin	NN	B-NP
O	403	405	RU	RU	NN	I-NP
O	405	406	-	-	HYPH	B-NP
O	406	409	486	486	CD	I-NP
O	410	418	inhibits	inhibit	VBZ	B-VP
O	419	422	the	the	DT	B-NP
O	423	432	induction	induction	NN	I-NP
O	433	435	of	of	IN	B-PP
O	436	440	VEGF	VEGF	NN	B-NP
O	441	444	and	and	CC	I-NP
O	445	448	TSP	TSP	NN	I-NP
O	448	449	-	-	HYPH	B-NP
O	449	450	1	1	CD	I-NP
O	451	453	by	by	IN	B-PP
O	454	464	progestins	progestin	NNS	B-NP
O	464	465	,	,	,	O
O	466	476	suggesting	suggest	VBG	B-VP
O	477	481	that	that	IN	B-SBAR
O	482	486	this	this	DT	B-NP
O	487	493	effect	effect	NN	I-NP
O	494	496	of	of	IN	B-PP
O	497	506	progestin	progestin	NN	B-NP
O	507	509	is	be	VBZ	B-VP
O	510	518	mediated	mediate	VBN	I-VP
O	519	521	by	by	IN	B-PP
O	522	525	the	the	DT	B-NP
O	526	538	progesterone	progesterone	NN	I-NP
O	539	547	receptor	receptor	NN	I-NP
O	548	549	(	(	(	O
O	549	551	PR	PR	NN	B-NP
O	551	552	)	)	)	O
O	552	553	.	.	.	O

O	554	565	Actinomycin	Actinomycin	NN	B-NP
O	565	566	-	-	HYPH	I-NP
O	566	567	D	D	NN	I-NP
O	567	568	,	,	,	O
O	569	572	but	but	CC	O
O	573	576	not	not	RB	O
O	577	586	puromycin	puromycin	NN	B-NP
O	586	587	,	,	,	O
O	588	592	also	also	RB	B-ADVP
O	593	599	blocks	block	VBZ	B-VP
O	600	609	progestin	progestin	NN	B-NP
O	609	610	-	-	HYPH	I-NP
O	610	619	dependent	dependent	JJ	I-NP
O	620	629	induction	induction	NN	I-NP
O	630	632	of	of	IN	B-PP
O	633	636	TSP	TSP	NN	B-NP
O	636	637	-	-	HYPH	B-NP
O	637	638	1	1	CD	I-NP
O	638	639	.	.	.	O

O	640	641	A	A	DT	B-NP
O	642	650	putative	putative	JJ	I-NP
O	651	660	progestin	progestin	NN	I-NP
O	660	661	-	-	HYPH	B-NP
O	661	669	response	response	NN	I-NP
O	670	677	element	element	NN	I-NP
O	678	681	was	be	VBD	B-VP
O	682	692	identified	identify	VBN	I-VP
O	693	695	in	in	IN	B-PP
O	696	699	the	the	DT	B-NP
O	700	705	human	human	JJ	I-NP
O	706	709	TSP	TSP	NN	I-NP
O	709	710	-	-	HYPH	B-NP
O	710	711	1	1	CD	I-NP
O	712	720	promoter	promoter	NN	I-NP
O	720	721	,	,	,	O
O	722	727	which	which	WDT	B-NP
O	728	730	is	be	VBZ	B-VP
O	731	741	consistent	consistent	JJ	B-ADJP
O	742	746	with	with	IN	B-PP
O	747	750	the	the	DT	B-NP
O	751	761	hypothesis	hypothesis	NN	I-NP
O	762	766	that	that	IN	B-SBAR
O	767	768	a	a	DT	B-NP
O	769	778	progestin	progestin	NN	I-NP
O	778	779	-	-	HYPH	I-NP
O	779	781	PR	PR	NN	I-NP
O	782	789	complex	complex	NN	I-NP
O	790	795	might	might	MD	B-VP
O	796	804	directly	directly	RB	I-VP
O	805	813	regulate	regulate	VB	I-VP
O	814	827	transcription	transcription	NN	B-NP
O	828	830	of	of	IN	B-PP
O	831	834	the	the	DT	B-NP
O	835	838	TSP	TSP	NN	I-NP
O	838	839	-	-	HYPH	B-NP
O	839	840	1	1	CD	I-NP
O	841	845	gene	gene	NN	I-NP
O	846	848	in	in	IN	B-PP
O	849	854	human	human	JJ	B-NP
B-Cell	855	860	cells	cell	NNS	I-NP
O	860	861	.	.	.	O

O	862	873	Conditioned	Conditioned	JJ	B-NP
O	874	880	medium	medium	NN	I-NP
O	881	885	from	from	IN	B-PP
O	886	895	progestin	progestin	NN	B-NP
O	895	896	-	-	HYPH	B-NP
O	896	903	treated	treat	VBN	I-NP
B-Cell	904	910	breast	breast	NN	I-NP
I-Cell	911	917	cancer	cancer	NN	I-NP
I-Cell	918	923	cells	cell	NNS	I-NP
O	924	934	stimulates	stimulate	VBZ	B-VP
B-Cell	935	946	endothelial	endothelial	JJ	B-NP
I-Cell	947	951	cell	cell	NN	I-NP
O	952	965	proliferation	proliferation	NN	I-NP
O	966	968	in	in	IN	B-PP
O	969	972	the	the	DT	B-NP
O	973	980	absence	absence	NN	I-NP
O	981	987	though	though	IN	B-SBAR
O	988	991	not	not	RB	O
O	992	994	in	in	IN	B-PP
O	995	998	the	the	DT	I-PP
O	999	1007	presence	presence	NN	I-PP
O	1008	1010	of	of	IN	I-PP
O	1011	1019	antibody	antibody	NN	B-NP
O	1020	1022	to	to	TO	B-PP
O	1023	1026	TSP	TSP	NN	B-NP
O	1026	1027	-	-	HYPH	B-NP
O	1027	1028	1	1	CD	I-NP
O	1028	1029	,	,	,	O
O	1030	1040	indicating	indicate	VBG	B-VP
O	1041	1045	that	that	IN	B-SBAR
O	1046	1049	TSP	TSP	NN	B-NP
O	1049	1050	-	-	HYPH	B-NP
O	1050	1051	1	1	CD	I-NP
O	1052	1060	secreted	secrete	VBN	B-VP
O	1061	1063	by	by	IN	B-PP
B-Cell	1064	1070	breast	breast	NN	B-NP
I-Cell	1071	1077	cancer	cancer	NN	I-NP
I-Cell	1078	1083	cells	cell	NNS	I-NP
O	1084	1089	could	could	MD	B-VP
O	1090	1092	be	be	VB	I-VP
O	1093	1096	pro	pro	AFX	B-ADJP
O	1096	1097	-	-	HYPH	I-ADJP
O	1097	1107	angiogenic	angiogenic	JJ	I-ADJP
O	1107	1108	.	.	.	O

O	1109	1114	Since	Since	IN	B-SBAR
B-Cell	1115	1120	tumor	tumor	NN	B-NP
I-Cell	1121	1125	cell	cell	NN	I-NP
O	1125	1126	-	-	HYPH	B-VP
O	1126	1133	derived	derive	VBN	B-NP
O	1134	1137	TSP	TSP	NN	I-NP
O	1137	1138	-	-	HYPH	B-NP
O	1138	1139	1	1	CD	I-NP
O	1140	1143	has	have	VBZ	B-VP
O	1144	1147	the	the	DT	B-NP
O	1148	1157	potential	potential	NN	I-NP
O	1158	1160	to	to	TO	B-VP
O	1161	1168	promote	promote	VB	I-VP
O	1169	1181	angiogenesis	angiogenesis	NN	B-NP
O	1182	1184	in	in	IN	B-PP
O	1185	1188	the	the	DT	B-NP
B-Cancer	1189	1194	tumor	tumor	NN	I-NP
O	1195	1211	microenvironment	microenvironment	NN	I-NP
O	1211	1212	,	,	,	O
O	1213	1215	it	it	PRP	B-NP
O	1216	1221	could	could	MD	B-VP
O	1222	1224	be	be	VB	I-VP
O	1225	1226	a	a	DT	B-NP
O	1227	1236	potential	potential	JJ	I-NP
O	1237	1243	target	target	NN	I-NP
O	1244	1247	for	for	IN	B-PP
B-Cancer	1248	1254	breast	breast	NN	B-NP
I-Cancer	1255	1261	cancer	cancer	NN	I-NP
O	1262	1269	therapy	therapy	NN	I-NP
O	1269	1270	.	.	.	O

